Calcitonin Evidence Guide
Calcitonin (Miacalcin/Fortical) is FDA-approved for postmenopausal osteoporosis and Paget's disease, with decades of clinical data supporting its antiresorptive and analgesic effects. It is no longer considered a first-line osteoporosis agent - bisphosphonates and denosumab have superior fracture reduction data - but it retains approval and a valid evidence base. For calcitonin receptor pharmacology and pain modulation research, it is the reference compound.
Our Take
Calcitonin (Miacalcin/Fortical) is FDA-approved for postmenopausal osteoporosis and Paget's disease, with decades of clinical data supporting its antiresorptive and analgesic effects. It is no longer considered a first-line osteoporosis agent - bisphosphonates and denosumab have superior fracture reduction data - but it retains approval and a valid evidence base. For calcitonin receptor pharmacology and pain modulation research, it is the reference compound.
- Best for
- Postmenopausal osteoporosis (second-line), Paget's disease, hypercalcemia of malignancy, bone pain modulation
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 200 IU intranasal daily (osteoporosis) or 100 IU IM/subcutaneous (Paget's/hypercalcemia)
Benefits and Evidence
- Bone Pain Reduction: Level A, includes human evidence - Provides significant analgesic effect in Paget's disease and acute vertebral compression fractures. Pain relief often occurs before measurable changes in bone turnover markers.
- Osteoporosis Fracture Reduction: Level A, includes human evidence - PROOF trial showed 33% reduction in vertebral fractures with nasal calcitonin 200 IU daily. However, effect on non-vertebral and hip fractures not demonstrated. Less effective than bisphosphonates.
- Paget's Disease Biochemical Response: Level A, includes human evidence - Reduces serum alkaline phosphatase and urinary hydroxyproline in Paget's disease. Clinical improvement in bone pain, neurological complications, and high-output cardiac failure.
- Cancer Risk Concern: Level B, includes human evidence - EMA review identified a small but statistically significant increase in cancer risk with long-term calcitonin use. Led to restrictions on long-term use in some countries.
Side Effects and Warnings
- Nasal irritation and rhinitis (nasal spray)
- Nausea
- Facial flushing
- Injection site reactions
- Diarrhea
- Urinary frequency
- Potential small increased cancer risk with long-term use (EMA warning)
- Not recommended as first-line osteoporosis therapy - use bisphosphonates first
Research Dosage References
- <strong>Intranasal spray</strong> - 200 IU (1 spray) - Once daily (alternating nostrils) - For postmenopausal osteoporosis. Available as Miacalcin or Fortical nasal sprays. Supplement with calcium and vitamin D.
- <strong>Subcutaneous/Intramuscular injection</strong> - 100 IU - Once daily - For Paget's disease. May reduce to 50 IU daily or 100 IU every other day once response achieved.
- <strong>Subcutaneous/Intramuscular injection</strong> - 4 IU/kg - Every 12 hours - For acute hypercalcemia. May increase to 8 IU/kg every 6 hours if response inadequate after 1-2 days.
Mechanism of Action
Calcitonin regulates calcium metabolism through direct osteoclast inhibition: 1. Osteoclast inhibition: Binds to calcitonin receptors (CTR) on osteoclasts, rapidly inhibiting bone resorption by disrupting the ruffled border and reducing acid secretion. 2. Renal calcium excretion: Promotes urinary calcium excretion by inhibiting tubular calcium reabsorption, contributing to serum calcium lowering. 3. Analgesic effect: Provides pain relief in Paget's disease and vertebral fractures through a mechanism possibly involving central endorphin-mediated pathways. 4. Transient effect: Osteoclasts develop receptor downregulation (escape phenomenon) with continuous exposure, limiting long-term efficacy for bone density improvement.
Legal Status
FDA-approved for postmenopausal osteoporosis (when alternative treatments are unsuitable), Paget's disease of bone, and hypercalcemia. Available by prescription. Generic versions available. Restricted in EU to short-term use only.
Primary Sources
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis (PROOF). Am J Med, 2000.
- Calcitonin for Paget's disease of bone. Bone, 2006.
- Calcitonin for the treatment and prevention of osteoporotic fractures. Cochrane Database Syst Rev, 2012.